GLP-1<\/a> receptor agonist designed for weight management in adults with obesity or who are overweight.<\/p>\nNovo Nordisk’s pill was launched on January 5, 2026 in America, and hit over 26,000 U.S. prescriptions in the second full week, IQVIA data revealed.<\/p>\n
Sharon, an enterprise procurement specialist, from Greenville, South Carolina, said: “As soon as I heard Wegovy was coming out with a pill, I saw my doctor, who gave me a prescription on them.<\/p>\n
“I went straight to the pharmacy, but they had sold out, so I went back a few days later and managed to get them.<\/p>\n
“At day five of taking the pills, it shut out food noise completely.<\/p>\n
“I am not snacking as much as I used to; hours could pass by, and I won’t even think of food.<\/p>\n
“I have no side effects, I workout every day, and have loads of energy – I have lost 2lbs so far.”<\/p>\n
![\"image\"](\"data:image\/png;base64,iVBORw0KGgoAAAANSUhEUgAAAAQAAAADCAQAAAAe\/WZNAAAAEElEQVR42mM8U88ABowYDABAxQPltt5zqAAAAABJRU5ErkJggg==\")
<\/p>\n
(Novo Nordisk via SWNS)<\/p>\n
By Talker<\/p>\n
The Wegovy pill is set to be one of the most popular weight-loss treatments if approved in the UK because of the easy oral use and it’s appeal to people who don’t like the idea of daily injections.<\/p>\n
Both the Wegovy pen and pill use semaglutide – an ingredient that mimics a hormone found in the gut. It controls hunger signals and helps users lose weight by reducing the appetite.<\/p>\n
It’s likely that the criteria to be eligible for the Wegovy pill will be similar to the Wegovy pen.<\/p>\n
Currently, the government guidelines state that adults “with a weight-related health condition \u2013 such as hypertension or cardiovascular disease and a Body Mass Index (BMI) of at least 35, or, exceptionally, a BMI of 30, if they meet the criteria for specialist weight management services,” may be able to qualify for a Wegovy pen prescription on the NHS.<\/p>\n
Like the Wegovy pen, its expected that the pill will also to be available privately in the UK if it’s approved.<\/p>\n
Currently, in America, the Wegovy pill starts at $139 a month (roughly \u00a3104). The pen starts at $199 (\u00a3149).<\/p>\n
Going off this pricing, it’s likely that if the pill is approved in the UK, it will be a cheaper option than the pen.<\/p>\n
While some sources are claiming approval is set to be confirmed in the UK within the next few days, a Novo Nordisk spokesperson told us they “can not confirm the date of approval at this stage.”<\/p>\n","protected":false},"excerpt":{"rendered":"(Novo Nordisk via SWNS) By Talker A mom in America who couldn’t afford GLP-1 injections has started the…\n","protected":false},"author":2,"featured_media":103772,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_share_on_mastodon":"0"},"categories":[271],"tags":[699,698,52952,691,52950,393,692,700,52951,702,690,696,694,272,17607,695,693,697,689,280],"class_list":["post-103771","post","type-post","status-publish","format-standard","has-post-thumbnail","category-novo-nordisk","tag-chemicals-in-medicine","tag-clinical-medicine","tag-combined-oral-contraceptive-pill","tag-drugs","tag-glp-1-receptor-agonist","tag-health","tag-health-care","tag-health-care-industry","tag-human-body-weight","tag-medical-specialties","tag-medical-treatments","tag-medicinal-chemistry","tag-medicine","tag-novo-nordisk","tag-nutrition","tag-pharmaceutical-sciences","tag-pharmacology","tag-pharmacy","tag-semaglutide","tag-weight-loss"],"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@dk\/116720964012712073","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts\/103771","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/comments?post=103771"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts\/103771\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/media\/103772"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/media?parent=103771"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/categories?post=103771"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/tags?post=103771"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}